Uridine for Health & Longevity - Quick Reference Sheet

Uridine for Health & Longevity

Created on 07/23/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A natural building block of genetic material that the body also uses to build brain-cell membranes and connections. Generally well tolerated, but human evidence is thin and comes mostly from combination products in early memory loss, with small, inconsistent benefits. Mechanistically promising yet clinically unproven — best seen as active, unsettled research. (Full Review)

Protocol

Form
UMP or TAU
Plain uridine poorly absorbed in adults; UMP or TAU preferred
Dose
150–1,000 mg/day UMP
250–500 mg once daily most common; TAU ~25–150 mg
Combine
With DHA + choline
Most-studied membrane-precursor stack; avoid uridine in isolation
Time to effect
Subjective effects
Days to weeks
Cognitive/mood effects reported gradually, not acutely
Cognitive trials
Months
Membrane-precursor mechanisms are inherently slow
Self-trial
8–12 weeks
Defined period to assess subjective cognitive or mood effects

Benefits

Contraindications
  • Fluoropyrimidine chemotherapy (fluorouracil, capecitabine)
  • Active malignancy
  • Bipolar-spectrum disorders
  • Pregnancy and breastfeeding
Key Interactions
  • Nucleoside-analog / antiviral drugs (stavudine, zidovudine)
  • Nucleoside-transport inhibitors (dipyridamole)
  • Choline sources / citicoline / alpha-GPC (over-stacking)
  • Omega-3 fatty acids (DHA, EPA)

Risk & Side Effects

  • High: [risks_high]
  • Medium: [risks_medium]
  • Low: Gastrointestinal upset at higher doses; metabolic effects — insulin resistance and hepatic fat
  • Speculative: Potential to support tumor nucleotide supply; mood activation or switch in the bipolar spectrum

Monitoring

Marker Target Why
Fasting glucose 75–90 mg/dL Screens for the insulin-resistance signal seen with high-dose uridine in animals
HbA1c < 5.4% Tracks longer-term blood sugar, catching metabolic drift the animal data flag
ALT / AST ALT < 25 U/L; AST < 25 U/L Detects hepatic fat/injury, the second animal metabolic concern
Triglycerides < 100 mg/dL Elevated triglycerides accompany hepatic fat accumulation
Uric acid 3.5–6.0 mg/dL General nucleotide-metabolism marker for high-intake users

Cadence: Baseline before starting; ~3 months after starting, then every 6–12 months (sooner if metabolic risk factors are present)

Qualitative Assessment

  • Memory and recall (subjective sharpness, word-finding)
  • Focus and mental clarity during typical tasks
  • Mood stability and motivation
  • Energy levels through the day
  • Sleep quality